Androgen receptor (AR), estrogen receptor (ER), and progesterone receptor (PR) are important hormone receptors, and their inhibition of them can improve the clinical outcomes in patients with hormone-dependent tumors, such as endocrine therapy in breast cancer and using apalutamide (AR inhibitor) for castration-sensitive prostate cancer [99]. This evidence concerns the gene NR4A1 and breast carcinoma.